Faeth Therapeutics grants 30,824 performance options

Faeth Therapeutics, Inc. granted PAO Josiah Craver a performance-based stock option covering 30,824 shares of common stock at an exercise price of $28.37 per share.

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. granted PAO Josiah Craver a performance-based stock option covering 30,824 shares of common stock at an exercise price of $28.37 per share. The option becomes exercisable only if the average Nasdaq closing price reaches $70.00 over 30 consecutive days and at least one year has passed, and is forfeited if the stock price hurdle is not achieved by the fourth anniversary or not met in connection with a qualifying Change in Control. Following this award, Craver holds 30,824 of these options directly.

Insider Trade Summary

Grant/Award: 30,824 shares

Grant/Award 1 txn

Insider Craver Josiah

Role PAO

Type	Security	Shares	Price	Value
Grant/Award	Performance-Based Stock Option (right to buy) F1, F2	30,824	$0.00	$0.00

Holdings After Transaction: Performance-Based Stock Option (right to buy) — 30,824 contracts (Direct)

Footnotes (2)

1. F1. Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety.
2. F2. In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety.

Key Figures

Performance options granted: 30,824 shares Exercise price: $28.37 per share Underlying common shares: 30,824 shares +3 more

6 metrics

Performance options granted 30,824 shares Performance-based stock option grant to PAO Josiah Craver

Exercise price $28.37 per share Exercise price of the performance-based stock option

Underlying common shares 30,824 shares Shares of common stock underlying the derivative award

Stock Price Hurdle $70.00 per share Average Nasdaq closing price required for vesting

Measurement period for hurdle 30 days Average closing price measured over 30 consecutive calendar days

Expiration date 2036-07-20 Expiry of the performance-based stock option

Key Terms

Performance-Based Stock Option, Stock Price Hurdle, Change in Control, Equity Incentive Plan

4 terms

Performance-Based Stock Option financial

"Represents a performance-based stock option that becomes exercisable, if at all, on the later"

Stock Price Hurdle financial

"equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary"

Change in Control financial

"In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Equity Incentive Plan financial

"Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Faeth Therapeutics (FTH) report for Josiah Craver?

Faeth Therapeutics reported that PAO Josiah Craver received a grant of 30,824 performance-based stock options with an exercise price of $28.37 per share. The options vest only if demanding stock price and service conditions are satisfied, otherwise they are forfeited.

How many Faeth Therapeutics (FTH) performance options were granted to Josiah Craver?

Josiah Craver was granted 30,824 performance-based stock options, each tied to one share of Faeth Therapeutics common stock. After this award, his directly held option position reported in this transaction totals 30,824 derivative securities.

What are the vesting conditions on Josiah Craver’s FTH performance-based options?

The options vest only if Faeth Therapeutics’ stock achieves an average Nasdaq closing price of at least $70.00 over 30 consecutive days and the first anniversary of grant has passed, with continued service. If the hurdle is not achieved by the fourth anniversary, the award is forfeited.

What is the exercise price of Josiah Craver’s Faeth Therapeutics (FTH) options?

The granted performance-based stock options have an exercise price of $28.37 per share. Each option is exercisable, if vesting conditions are met, into one share of Faeth Therapeutics common stock before the stated expiration date in 2036.

When do Josiah Craver’s Faeth Therapeutics performance options expire?

The reported performance-based stock options expire on 2036-07-20. They become exercisable only after the stock price and service requirements are satisfied; if the $70.00 stock price hurdle is never achieved within the performance period, the options are forfeited instead of expiring normally.

How does a Change in Control affect Josiah Craver’s FTH option grant?

If a Change in Control occurs before the performance period ends, the $70.00 Stock Price Hurdle is deemed achieved if per-share consideration equals or exceeds that amount. In that case, the option vests in full immediately before closing, subject to continued service; otherwise it is forfeited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:15 PM Accepted by SEC EDGAR 07/23/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Craver Josiah

(Last) (First) (Middle)

C/O FAETH THERAPEUTICS, INC.

701 TILLERY STREET #12 #1010

(Street)

AUSTIN TEXAS 78702

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Faeth Therapeutics, Inc. [ FTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance-Based Stock Option (right to buy)	$28.37	07/21/2026		A		30,824		(1)(2)	07/20/2036	Common Stock	30,824	$0	30,824	D

Explanation of Responses:

1. Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety.

2. In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety.

	/s/ Josiah Craver	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)